Compare BVS & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BVS | ENTA |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.9M | 486.3M |
| IPO Year | 2016 | 2012 |
| Metric | BVS | ENTA |
|---|---|---|
| Price | $8.46 | $13.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $13.33 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 285.6K | 184.0K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.46 | 29.93 |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $568,087,000.00 | $102,814,000.00 |
| Revenue This Year | $7.42 | $5.91 |
| Revenue Next Year | $6.46 | N/A |
| P/E Ratio | $27.65 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $5.81 | $4.09 |
| 52 Week High | $11.25 | $17.15 |
| Indicator | BVS | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 44.83 |
| Support Level | $6.42 | $13.39 |
| Resistance Level | $9.01 | $13.98 |
| Average True Range (ATR) | 0.38 | 0.86 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 18.94 | 15.79 |
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.